Premium
Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis
Author(s) -
KATIKIREDDI Veera S.,
WHITTLE Samuel L.,
HILL Catherine L.
Publication year - 2010
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/j.1756-185x.2009.01457.x
Subject(s) - medicine , rheumatoid arthritis , adverse effect , observational study , tuberculosis , risk factor , tumor necrosis factor alpha , intensive care medicine , randomized controlled trial , immunology , surgery , pathology
Tumour necrosis factor inhibitors have demonstrated significant clinical and radiological benefits in rheumatoid arthritis (RA). However, they have important adverse effects including an association with infection. Results from current studies, including meta‐analyses of randomized controlled trials and observational studies, are conflicting regarding the risk of serious infection in RA patients treated with TNF inhibitors. The majority of data suggest an increased risk, in particular of respiratory, skin and soft tissue infections, including tuberculosis. This increased risk of tuberculosis is of particular concern in the APLAR region. However, adverse event analysis remains a difficult area to study and decisions regarding initiation of TNF inhibitors must be made on a case‐by‐case basis after carefully considering the risks and benefits.